Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C13H9N5O6 |
Molar mass | 331.244 g·mol−1 |
3D model ( JSmol) | |
| |
|
Zonampanel ( INN, code name YM872) is a quinoxalinedione derivative drug and competitive antagonist of the AMPA receptor which was being investigated by Yamanouchi/ Astellas Pharma as a neuroprotective drug for the treatment of ischemic stroke but never completed clinical trials. [1] [2] [3] [4] In clinical trials, zonampanel produced severe side effects including hallucinations, agitation, and catatonia in patients, resulting in early termination of the trials. [5]